Monelli Filippo, Besutti Giulia, Djuric Olivera, Bonvicini Laura, Farì Roberto, Bonfatti Stefano, Ligabue Guido, Bassi Maria Chiara, Damato Angela, Bonelli Candida, Pinto Carmine, Pattacini Pierpaolo, Giorgi Rossi Paolo
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Radiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, AUSL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Cancers (Basel). 2021 May 7;13(9):2246. doi: 10.3390/cancers13092246.
This systematic review with meta-analysis aimed to assess the effect of diffuse liver diseases (DLD) on the risk of synchronous (S-) or metachronous (M-) liver metastases (LMs) in patients with solid neoplasms. Relevant databases were searched for systematic reviews and cross-sectional or cohort studies published since 1990 comparing the risk of LMs in patients with and without DLD (steatosis, viral hepatitis, cirrhosis, fibrosis) in non-liver solid cancer patients. Outcomes were prevalence of S-LMs, cumulative risk of M-LMs and LM-free survival. Risk of bias (ROB) was assessed using the Newcastle-Ottawa Scale. We report the pooled relative risks (RR) for S-LMs and hazard ratios (HR) for M-LMs. Subgroup analyses included DLD, primary site and continent. Nineteen studies were included ( = 37,591 patients), the majority on colorectal cancer. ROB appraisal results were mixed. Patients with DLD had a lower risk of S-LMs (RR 0.50, 95% CI 0.34-0.76), with a higher effect for cirrhosis and a slightly higher risk of M-LMs (HR 1.11 95% CI, 1.03-1.19), despite a lower risk of M-LMs in patients with vs without viral hepatitis (HR 0.57, 95% CI 0.40-0.82). There may have been a publication bias in favor of studies reporting a lower risk for patients with DLD. DLD are protective against S-LMs and slightly protective against M-LMs for viral hepatitis only.
本项系统评价及荟萃分析旨在评估弥漫性肝病(DLD)对实体瘤患者发生同时性(S-)或异时性(M-)肝转移(LM)风险的影响。检索了相关数据库,以查找自1990年以来发表的系统评价以及横断面研究或队列研究,这些研究比较了非肝脏实体癌患者中有无DLD(脂肪变性、病毒性肝炎、肝硬化、肝纤维化)的患者发生LM的风险。结局指标为S-LM的患病率、M-LM的累积风险和无LM生存期。使用纽卡斯尔-渥太华量表评估偏倚风险(ROB)。我们报告了S-LM的合并相对风险(RR)和M-LM的风险比(HR)。亚组分析包括DLD、原发部位和大洲。纳入了19项研究(n = 37,591例患者),大多数研究针对结直肠癌。ROB评估结果不一。DLD患者发生S-LM的风险较低(RR 0.50,95%CI 0.34-0.76),肝硬化患者的影响更大,发生M-LM的风险略高(HR 1.11,95%CI 1.03-1.19),尽管与无病毒性肝炎的患者相比,有病毒性肝炎的患者发生M-LM的风险较低(HR 0.57,95%CI 0.40-0.82)。可能存在有利于报告DLD患者风险较低的研究的发表偏倚。DLD对S-LM有保护作用,仅对病毒性肝炎导致的M-LM有轻微保护作用。